UNIVERSITY OF MINNESOTA
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma. is a funding opportunity from UNIVERSITY OF MINNESOTA, up to 485977, closing November 30, 2028.
Nov 30, 2028
(853d left)Overview
Project Summary/Abstract Vaccination is a potent regulator of the immune system and much research is being conducted to understand how antigen-specific stimulation can be used to induce and redirect anti-tumor immunity. Our team develops a cancer immunotherapy program using novel AAV vectors to deliver antigens both…